Table 1 Clinicopathological characteristics of 118 patients enrolled in the present investigation
| Â | Number of patients (%) |
|---|---|
Gender | Â |
Female | 31 (26.3%) |
Male | 87 (73.8%) |
Histological type | Â |
Clear cell RCC | 99 (83.9%) |
Papillary RCC | 9 (7.63%) |
Chromophobe RCC | 5 (4.24%) |
Other* | 5 (4.24%) |
Histological grade (Fuhrman) | Â |
I | 6 (5.08%) |
II | 46 (38.98%) |
III | 48 (40.68%) |
IV | 18 (15.25%) |
Stage | Â |
I | 28 (23.73%) |
II | 15 (12.71%) |
III | 24 (20.34%) |
IV | 39 (33.05%) |
Not available | 12 (10.17%) |
Lymph node metastasis | Â |
No | 73 (61.8%) |
Yes | 20 (17%) |
Not available | 25 (21.2%) |
Total number of metastases | Â |
Absence | 30 (25.42%) |
1 | 25 (21.19% |
2 | 24 (20.34%) |
3 | 11 (9.32%) |
4 | 4 (3.39%) |
Not available | 24 (20.24%) |
Disease progression | Â |
Absence | 19 (16.10%) |
Presence | 42 (35.60%) |
Not available | 57 (48.30%) |
Follow-up | Â |
Alive/censored | 43 (45.74%) Follow-up: 49Â months (6-108.8Â months) |
Dead of disease | 51 (54.26%) Follow-up: 30.37Â months (1.77-117.43Â months) |
| Â | Median (range) |
Age | 61 (30-80) |